← Back to Search

Monoclonal Antibodies

Zilovertamab Vedotin for Lymphoma

Phase 2
Waitlist Available
Research Sponsored by Merck Sharp & Dohme Corp.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Has adequate organ function.
Has relapsed or refractory (rr) DLBCL; has progressed after at least 2 lines of prior therapy; and has progressed after auto- stem cell transplant (SCT) or are auto-SCT ineligible. Must have received prior multiagent regimen that includes an alkylating agent, anthracycline, and anti-CD20 monoclonal antibody.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to approximately 50 months
Awards & highlights

Study Summary

This trial will test how well a new cancer drug called zilovertamab vedotin works and how safe it is.

Who is the study for?
This trial is for people with a type of cancer called Diffuse Large B-Cell Lymphoma (DLBCL) who have tried at least two treatments and are not eligible or didn't improve after stem cell transplant or CAR-T therapy. They should be able to do daily activities, have good organ function, measurable cancer signs on scans, and confirmed DLBCL diagnosis.Check my eligibility
What is being tested?
The study tests Zilovertamab Vedotin (MK-2140) in patients with DLBCL to see how well it works and how long the effects last. It's a Phase 2 trial where everyone gets the same treatment, and doctors check if tumors shrink using special criteria while also watching for any safety issues.See study design
What are the potential side effects?
While specific side effects aren't listed here, common ones from similar drugs include reactions at injection site, fatigue, nausea, low blood counts leading to infection risk or bleeding problems; nerve damage causing numbness or tingling; liver issues; and allergic reactions.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My organs are functioning well.
Select...
My DLBCL has not responded to at least 2 treatments, including a stem cell transplant or I'm ineligible for one.
Select...
I either did not respond to CAR-T therapy or am not eligible for it.
Select...
My DLBCL can be measured using scans.
Select...
My physical ability was assessed as able to care for myself up to being up and about more than half of waking hours, within the last week.
Select...
I have been diagnosed with diffuse large B-cell lymphoma.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to approximately 50 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to approximately 50 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Objective Response Rate (ORR) per Lugano Response Criteria
Secondary outcome measures
Duration of Response (DOR) per Lugano Response Criteria
Number of Participants Who Discontinue Study Treatment Due to an AE
Number of Participants Who Experience an Adverse Event (AE)

Trial Design

2Treatment groups
Experimental Treatment
Group I: Arm BExperimental Treatment1 Intervention
Participants will receive treatment with zilovertamab vedotin 2.25 mg/kg via intravenous (IV) infusion on Day 1 of each 21-day cycle (every 3 weeks (Q3W)) until documented disease progression or any other discontinuation criterion is met.
Group II: Arm AExperimental Treatment1 Intervention
Participants will receive treatment with zilovertamab vedotin 2.5 mg/kg via intravenous (IV) infusion on Day 1 of each 21-day cycle (every 3 weeks (Q3W)) until documented disease progression or any other discontinuation criterion is met.

Find a Location

Who is running the clinical trial?

Merck Sharp & Dohme Corp.Lead Sponsor
2,286 Previous Clinical Trials
4,581,771 Total Patients Enrolled
Merck Sharp & Dohme LLCLead Sponsor
3,862 Previous Clinical Trials
5,049,560 Total Patients Enrolled
Medical DirectorStudy DirectorMerck Sharp & Dohme LLC
2,769 Previous Clinical Trials
8,062,060 Total Patients Enrolled

Media Library

MK-2140 (zilovertamab vedotin) (Monoclonal Antibodies) Clinical Trial Eligibility Overview. Trial Name: NCT05144841 — Phase 2
B-Cell Lymphoma Research Study Groups: Arm A, Arm B
B-Cell Lymphoma Clinical Trial 2023: MK-2140 (zilovertamab vedotin) Highlights & Side Effects. Trial Name: NCT05144841 — Phase 2
MK-2140 (zilovertamab vedotin) (Monoclonal Antibodies) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05144841 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Has MK-2140 (zilovertamab vedotin) been formally sanctioned by the FDA?

"There is a limited amount of evidence suggesting the safety of MK-2140 (zilovertamab vedotin), thus it received an assessment score of 2. No data exists that confirms its efficacy."

Answered by AI

How many institutes are participating in the experiment?

"The clinical trial is being conducted in multiple sites throughout the US, including AHN West Penn Hospital (Site 0212) in Pittsburgh, Pennsylvania; Saint Louis University Cancer Center ( Site 0209) in St. Louis, Missouri; and St. Joseph Hospital-The Center for Cancer Prevention and Treatment ( Site 0229) located in Orange , California amongst 16 other locations."

Answered by AI

How many volunteers are participating in this research initiative?

"The sponsor of this trial, Merck Sharp & Dohme Corp., is in search of a total 100 patients who meet the criteria to partake. Patients can be seen at AHN West Penn Hospital ( Site 0212) in Pittsburgh, Pennsylvania and Saint Louis University Cancer Center (Site 0209) in Saint Louis, Missouri amongst other locations."

Answered by AI

Is recruitment still ongoing for this investigation?

"Affirmative. The information hosted on clinicaltrials.gov states that this medical research is currently recruiting volunteers, and was first posted in the 8th of January 2022 with an update made at 24th November 2022. To be precise, 100 individuals are desired to join from 16 different trial sites."

Answered by AI
~48 spots leftby Jun 2025